{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:42:10Z","timestamp":1792896130278,"version":"4.5.0"},"reference-count":103,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Graft-versus-host disease (GVHD) is a significant cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). For many years, corticosteroids have been the mainstay treatment for GVHD, but cases of steroid-refractory GVHD and the severe adverse effects of high-dose corticosteroids have increased the need for preventative and therapeutic strategies for GVHD. Due to the nature of alloreactive T cells, GVHD is inherently linked to the graft-versus-leukemia (GVL) effect, the therapeutic driving force behind stem cell transplantation. A considerable clinical challenge is to preserve GVL while suppressing GVHD. The field of GVHD research has greatly expanded over the past decades, including advancements in T cell modulation and depletion, antibody therapies, chemotherapeutics, cellular therapies, and Janus kinase inhibition. In this review, we discuss current approaches and advances in the prophylaxis and treatment of GVHD with a focus on new emerging advancements in Janus kinase inhibitor therapy.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1304065","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:01:11Z","timestamp":1707177671000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Janus kinase inhibition in the treatment and prevention of graft-versus-host disease"],"prefix":"10.3389","volume":"15","author":[{"given":"Elisa","family":"De Togni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oladipo","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramzi","family":"Abboud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.06.014","article-title":"Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning","volume":"18","author":"Weisdorf","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-versus-host disease","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1609337","article-title":"Acute graft-versus-host disease \u2014 Biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-737700","article-title":"Genome-wide minor histocompatibility matching as related to the risk of graft-versus-host disease","volume":"129","author":"Martin","year":"2017","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2003.10.006","article-title":"Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation","volume":"10","author":"Couriel","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.5045\/br.2022.2022194","article-title":"Reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for patients with myelofibrosis","volume":"57","author":"Kim","year":"2022","journal-title":"Blood Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.11483","article-title":"Acute graft versus host disease: A comprehensive review","volume":"37","author":"Nassereddine","year":"2017","journal-title":"Anticancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-015-1785-1","article-title":"State-of-the-art acute and chronic GVHD treatment","volume":"101","author":"Jamil","year":"2015","journal-title":"Int J Hematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-302109","article-title":"Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria","volume":"117","author":"Flowers","year":"2011","journal-title":"Blood"},{"key":"B11","article-title":"Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides","author":"Bolon","year":"2022"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-07-686642","article-title":"Classification systems for chronic graft-versus-host disease","volume":"129","author":"Lee","year":"2017","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.10.021","article-title":"Increasing incidence of chronic graft-versus-host disease inAllogeneic transplantation: A report from the center for international blood and marrow transplant research","volume":"21","author":"Arai","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.7212","article-title":"Long-term survival and late deaths after allogeneic hematopoietic cell transplantation","volume":"29","author":"Wingard","year":"2011","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.21.8555","article-title":"ISGF3, the transcriptional activator induced by interferon alpha, consists of multiple interacting polypeptide chains","volume":"87","author":"Fu","year":"1990","journal-title":"Proc Natl Acad Sci"},{"key":"B16","doi-asserted-by":"publisher","first-page":"a011205","DOI":"10.1101\/cshperspect.a011205","article-title":"The JAK\/STAT pathway","volume":"4","author":"Harrison","year":"2012","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2008.08.010","article-title":"Inteferons pen the JAK\u2013STAT pathway","volume":"19","author":"Schindler","year":"2008","journal-title":"Semin Cell Dev Biol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81166-6","article-title":"Disruption of the jak1 gene demonstrates obligatory and nonredundant roles of the jaks in cytokine-induced biologic responses","volume":"93","author":"Rodig","year":"1998","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81167-8","article-title":"Jak2 is essential for signaling through a variety of cytokine receptors","volume":"93","author":"Parganas","year":"1998","journal-title":"Cell"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1126\/science.270.5237.794","article-title":"Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking jak3","volume":"270","author":"Thomis","year":"1995","journal-title":"Sci (80- )"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1126\/science.270.5237.800","article-title":"Defective lymphoid development in mice lacking jak3","volume":"270","author":"Nosaka","year":"1995","journal-title":"Science"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(95)90066-7","article-title":"Developmental defects of lymphoid cells in Jak3 kinase-deficient mice","volume":"3","author":"Park","year":"1995","journal-title":"Immunity"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.08.004","article-title":"JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition","volume":"148","author":"Luo","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O\u2019Shea","year":"2015","journal-title":"Annu Rev Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-543736","article-title":"Activity of therapeutic JAK 1\/2 blockade in graft-versus-host disease","volume":"123","author":"Spoerl","year":"2014","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1177\/2040620720914489","article-title":"Insights into the role of the JAK\/STAT signaling pathway in graft- versus -host disease","volume":"11","author":"Abboud","year":"2020","journal-title":"Ther Adv Hematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI43706","article-title":"Absence of Stat1 in donor CD4+ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice","volume":"121","author":"Ma","year":"2011","journal-title":"J Clin Invest"},{"key":"B28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cellimm.2011.01.008","article-title":"Sequential activation of inflammatory signaling pathways during graft-versus-host disease (GVHD): Early role for STAT1 and STAT3","volume":"268","author":"Ma","year":"2011","journal-title":"Cell Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.bbmt.2018.08.018","article-title":"Comparative analysis of calcineurin inhibitor\u2013based methotrexate and mycophenolate mofetil\u2013containing regimens for prevention of graft-versus-host disease after reduced-intensity conditioning allogeneic transplantation","volume":"25","author":"Chhabra","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.7.2303","article-title":"Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation","volume":"92","author":"Ratanatharathorn","year":"1998","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.6.2062","article-title":"Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors","volume":"96","author":"Nash","year":"2000","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"key":"B33","first-page":"57","article-title":"Studies on the mechanism of action of cytoxan. Evidence of activation in vivo and in vitro","volume":"21","author":"Foley","year":"1961","journal-title":"Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic Malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007535","article-title":"Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: The BMT CTN 1101 trial","volume":"137","author":"Fuchs","year":"2021","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101093","article-title":"Relapse after allogeneic transplantation with post-transplant cyclophosphamide: Shattering myths and evolving insight","volume":"62","author":"McCurdy","year":"2023","journal-title":"Blood Rev"},{"key":"B38","doi-asserted-by":"publisher","first-page":"9636897221139104","DOI":"10.1177\/09636897221139103","article-title":"Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide as an effective regimen for prophylaxis of graft versus host disease after haploidentical peripheral blood stem cell transplantation with maternal\/collateral related donors","volume":"31","author":"Li","year":"2022","journal-title":"Cell Transplant"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003779","article-title":"A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation","volume":"5","author":"Bejanyan","year":"2021","journal-title":"Blood Adv"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01725-3","article-title":"Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia","volume":"57","author":"Lazzari","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.683263","article-title":"The addition of sirolimus to GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation: A meta-analysis of efficacy and safety","volume":"11","author":"Chen","year":"2021","journal-title":"Front Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05206-5","article-title":"Poor graft function after haploidentical stem cell transplantation with post-transplant cyclophosphamide","volume":"102","author":"G\u00f3mez-Centuri\u00f3n","year":"2023","journal-title":"Ann Hematol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.03.019","article-title":"Fresh or cryopreserved CD34+-selected mobilized peripheral blood stem and progenitor cells for the treatment of poor graft function after allogeneic hematopoietic cell transplantation","volume":"23","author":"Ghobadi","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B44","doi-asserted-by":"publisher","first-page":"S296","DOI":"10.1016\/j.bbmt.2019.12.573","article-title":"Can planned CD34+ Stem cell boost prevent poor graft function after peripheral blood haploidentical hematopoietic transplantation","volume":"26","author":"Abboud","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101092","article-title":"Does PTCY increase the risk of infections","author":"Mikulska","year":"2023","journal-title":"Blood Rev"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.732826","article-title":"and CMV-specific immune reconstitution following haploidentical stem cell transplantation: an update","volume":"12","author":"Luo","year":"2021","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.583","article-title":"Post transplantation cyclophosphamide (PTCY) is associated with increased risk of BK virus-associated hemorrhagic cystitis (BKHC) in patients undergoing allogeneic hematopoietic stem cell transplant (HSCT)","volume":"25","author":"Jahangiri","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1126\/science.164.3877.316","article-title":"Graft versus host inhibition: fetal liver and thymus cells to minimize secondary disease","volume":"164","author":"Bortin","year":"1969","journal-title":"Sci (80- )"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/s0140-6736(81)90647-4","article-title":"Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells","volume":"1981","author":"Reisner","year":"8242","journal-title":"Lancet (London England)"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13868","article-title":"The evolution of T-cell depletion in haploidentical stem-cell transplantation","volume":"172","author":"Or-Geva","year":"2016","journal-title":"Br J Haematol"},{"key":"B51","volume-title":"FDA approves abatacept for prophylaxis of acute graft versus host disease","year":"2021"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01086","article-title":"Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD","volume":"39","author":"Watkins","year":"2021","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010545","article-title":"PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation","volume":"7","author":"Al-Homsi","year":"2023","journal-title":"Blood Adv"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2027372","article-title":"Dipeptidyl peptidase 4 inhibition for prophylaxis of acute graft-versus-host disease","volume":"384","author":"Farag","year":"2021","journal-title":"N Engl J Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000893","article-title":"Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation","volume":"3","author":"Chen","year":"2019","journal-title":"Blood Adv"},{"key":"B56","unstructured":"ChenY-B\n          Vedolizumab for prophylaxis of lower gastrointestinal (GI) acute graft-versus-host disease (aGvHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) from unrelated donors: results of a phase 3, randomized, double-blind, placebo-controll2023"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30221-7","article-title":"Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with","volume":"6","author":"Bola\u00f1os-Meade","year":"2019","journal-title":"Lancet Haematol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.605726","article-title":"GVHD prophylaxis 2020","volume":"12","author":"Gooptu","year":"2021","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000035","article-title":"Managing cytokine release syndrome associated with novel T cell-engaging therapies","volume":"20","author":"Maude","year":"2014","journal-title":"Cancer J"},{"key":"B61","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1128\/MMBR.05015-11","article-title":"Into the eye of the cytokine storm","volume":"76","author":"Tisoncik","year":"2012","journal-title":"Microbiol Mol Biol Rev"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","article-title":"Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)","volume":"94","author":"Winkler","year":"1999","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119110","article-title":"Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a\/CD18 (LFA-1) on NK cells","volume":"98","author":"Wing","year":"1996","journal-title":"J Clin Invest."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-485623","article-title":"Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy","volume":"121","author":"Teachey","year":"2013","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.08.010","article-title":"Cytokine release syndrome after haploidentical stem cell transplantation","volume":"22","author":"Teachey","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa063842","article-title":"Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412","volume":"355","author":"Suntharalingam","year":"2006","journal-title":"N Engl J Med"},{"key":"B67","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.637.637","article-title":"Preliminary results of a phase 1 study of flotetuzumab, a CD123 x CD3 bispecific dart\u00ae Protein, in patients with relapsed\/refractory acute myeloid leukemia and myelodysplastic syndrome","volume":"130","author":"Uy","year":"2017","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.06.010","article-title":"Severe cytokine-release syndrome after T cell\u2013replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti\u2013IL-6 therapy is safe and well tolerated","volume":"22","author":"Abboud","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71017-4","article-title":"Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1\/2 trial","volume":"15","author":"Kennedy","year":"2014","journal-title":"Lancet Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009050","article-title":"A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin\/methotrexate GVHD prophylaxis","volume":"137","author":"Kennedy","year":"2021","journal-title":"Blood"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2020.1740592","article-title":"Ruxolitinib for the treatment of graft-versus-host disease","volume":"16","author":"Ali","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-403196","article-title":"IFN\u03b3R signaling mediates alloreactive T-cell trafficking and GVHD","volume":"120","author":"Choi","year":"2012","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0109799","article-title":"Pharmacologic blockade of JAK1\/JAK2 reduces gvHD and preserves the graft-versus-leukemia effect","volume":"9","author":"Choi","year":"2014","journal-title":"Boussiotis VA Ed PloS One"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2758","article-title":"Pharmacologic inhibition of JAK1\/JAK2 signaling reduces experimental murine acute GVHD while preserving GVT effects","volume":"21","author":"Carniti","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B77","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.exphem.2021.03.004","article-title":"Preclinical evaluation of JAK1\/2 inhibition by ruxolitinib in a murine model of chronic graft-versus-host disease","volume":"98","author":"Ryu","year":"2021","journal-title":"Exp Hematol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0123-z","article-title":"Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease","volume":"32","author":"Choi","year":"2018","journal-title":"Leukemia"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26291","article-title":"Targeting IFNGR\/IL6R or downstream JAK1\/JAK2 to control GvHD","volume":"9","author":"Ashami","year":"2018","journal-title":"Oncotarget"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01360-9","article-title":"Baricitinib prevents GvHD by increasing Tregs via JAK3 and treats established GvHD by promoting intestinal tissue repair via EGFR","volume":"36","author":"Kim","year":"2022","journal-title":"Leukemia"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173505","article-title":"Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases","volume":"885","author":"Covington","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1739","article-title":"Itacitinib (INCB039110), a JAK1 inhibitor, reduces cytokines associated with cytokine release syndrome induced by CAR T-cell therapy","volume":"26","author":"Huarte","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.151126","article-title":"Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis","volume":"102","author":"Mascarenhas","year":"2017","journal-title":"Haematologica"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01363-1","article-title":"Itacitinib prevents xenogeneic GVHD in humanized mice","volume":"56","author":"Courtois","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-116342","article-title":"Results from REACH1, a single-arm phase 2 study of ruxolitinib in combination with corticosteroids for the treatment of steroid-refractory acute graft-vs-host disease","volume":"132","author":"Jagasia","year":"2018","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001043","article-title":"A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease","volume":"4","author":"Schroeder","year":"2020","journal-title":"Blood Adv"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017442","article-title":"Effective treatment of low-risk acute GVHD with itacitinib monotherapy","volume":"141","author":"Etra","year":"2023","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00367-7","article-title":"Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial","volume":"9","author":"Zeiser","year":"2022","journal-title":"Lancet Haematol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1159\/000506758","article-title":"A prospective pilot study of graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and ruxolitinib in patients with myelofibrosis","volume":"144","author":"Morozova","year":"2021","journal-title":"Acta Haematol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005035","article-title":"Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study","volume":"6","author":"Ali","year":"2022","journal-title":"Blood Adv"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180423","article-title":"Maintenance ruxolitinib is associated with low rates of chronic gvhd requiring systemic treatment in older adults with AML\/MDS undergoing allogeneic HCT: results of a phase II multicenter trial","volume":"142","author":"Defilipp","year":"2023","journal-title":"Blood"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-178645","article-title":"2103 updated findings of a phase II study of ruxolitinib pre-, during- and post-hematopoietic stem cell transplantation for patients with primary or secondary myelofibrosis","author":"Hobbs","year":"2023","journal-title":"ASH Abstr"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157214","article-title":"Phase I study of baricitinib gvhd prophylaxis in HLA-matched, peripheral blood allogeneic hematopoietic cell transplant","volume":"140","author":"Schroeder","year":"2022","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4725","article-title":"Pacritinib combined with sirolimus and low-dose tacrolimus for GVHD prevention after allogeneic hematopoietic cell transplantation: preclinical and phase I trial results","volume":"27","author":"Pidala","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180289","article-title":"Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome with T-cell replete peripheral blood haploidentical transplantation","volume":"142","author":"Abboud","year":"2023","journal-title":"Blood"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-6367(22)00553-X","article-title":"Prolonged post-transplant ruxolitinib therapy is associated with protection from severe gvhd after allogeneic HCT","volume":"28","author":"DeFilipp","year":"2022","journal-title":"ASTCT Abstr"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-144591","article-title":"A single-arm, open-label, pilot study of the JAK1 selective inhibitor itacitinib for the prophylaxis of graft-versus-host disease and cytokine release syndrome in T-cell replete haploidentical peripheral blood hematopoietic cell transplantation","volume":"138","author":"Abboud","year":"2021","journal-title":"Blood"},{"key":"B101","article-title":"NCT04339101 - Itacitinib, tacrolimus, and sirolimus for the prevention of GVHD in patients with acute leukemia, myelodysplastic syndrome, or myelofibrosis undergoing reduced intensity conditioning donor stem cell transplantation","author":"Ali","year":"2022","journal-title":"Larvol Clin"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-02165-3","article-title":"Belumosudil and ruxolitinib combination for treatment of refractory chronic graft-versus-host disease","author":"Pusic","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-165547","article-title":"Belumosudil combination therapy in refractory chronic graft-versus-host disease","volume":"140","author":"Chin","year":"2022","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1304065\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:01:16Z","timestamp":1707177676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1304065\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,6]]},"references-count":103,"alternative-id":["10.3389\/fimmu.2024.1304065"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1304065","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,6]]},"article-number":"1304065"}}